Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Haemonetics Co. stock logo
HAE
Haemonetics
$93.25
-2.0%
$83.59
$70.74
$97.13
$4.74B0.34458,956 shs911,085 shs
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$24.91
-0.7%
$32.95
$22.36
$50.78
$1.96B1.17823,586 shs1.91 million shs
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$100.60
-1.1%
$100.79
$78.28
$212.43
$2.45B0.72253,271 shs521,388 shs
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$98.76
-7.0%
$110.75
$70.24
$132.92
$3.07B1.31434,096 shs601,028 shs
Nevro Corp. stock logo
NVRO
Nevro
$10.17
-11.8%
$13.21
$10.06
$28.89
$373.04M0.96505,310 shs1.11 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Haemonetics Co. stock logo
HAE
Haemonetics
-0.21%+3.37%+12.40%+23.36%+16.29%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
+8.38%-14.02%-26.24%-39.10%-50.21%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
+1.05%+3.93%+0.08%+5.13%-44.70%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-0.57%-3.07%-4.96%-11.40%-16.70%
Nevro Corp. stock logo
NVRO
Nevro
+3.41%+8.98%-13.24%-32.93%-57.98%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Haemonetics Co. stock logo
HAE
Haemonetics
4.0367 of 5 stars
2.32.00.04.32.71.72.5
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
4.9413 of 5 stars
4.03.00.04.02.81.73.8
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.6586 of 5 stars
2.51.00.03.91.92.51.9
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.9977 of 5 stars
3.51.00.00.01.00.80.6
Nevro Corp. stock logo
NVRO
Nevro
2.4011 of 5 stars
4.02.00.00.01.91.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6712.24% Upside
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
2.00
Hold$36.8047.73% Upside
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.00
Buy$123.0022.27% Upside
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
3.00
Buy$134.0035.68% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$20.0096.66% Upside

Current Analyst Ratings

Latest HAE, IART, NVRO, ICUI, and IRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $11.00
5/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $13.00
5/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$15.00 ➝ $12.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$37.00 ➝ $24.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$49.00 ➝ $40.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$37.00 ➝ $25.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$42.00 ➝ $26.00
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
5/7/2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$45.00 ➝ $25.00
5/3/2024
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$133.00 ➝ $122.00
5/3/2024
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$137.00 ➝ $138.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Haemonetics Co. stock logo
HAE
Haemonetics
$1.27B3.73$4.91 per share18.98$16.22 per share5.75
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$1.54B1.27$4.17 per share5.98$20.31 per share1.23
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$2.26B1.08$15.41 per share6.53$87.96 per share1.14
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$492.68M6.23N/AN/A$6.85 per share14.42
Nevro Corp. stock logo
NVRO
Nevro
$425.17M0.88N/AN/A$8.10 per share1.26

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4637.9121.992.239.97%22.37%9.71%5/9/2024 (Confirmed)
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$67.74M$0.8330.016.900.874.39%15.19%6.59%7/24/2024 (Estimated)
ICU Medical, Inc. stock logo
ICUI
ICU Medical
-$29.66M-$1.23N/A18.70N/A-1.31%6.35%3.03%8/5/2024 (Estimated)
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$123.41M-$4.23N/AN/AN/A-25.33%-69.87%-23.50%8/1/2024 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%8/6/2024 (Estimated)

Latest HAE, IART, NVRO, ICUI, and IRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024Q1 2024
Nevro Corp. stock logo
NVRO
Nevro
-$1.02-$0.70+$0.32-$0.70$97.90 million$101.90 million  
5/6/2024Q1 2024
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.55$0.55N/A$1.14$361.96 million$368.90 million    
2/28/202412/31/2023
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.90$0.89-$0.01$1.53$399.30 million$397.00 million    
2/27/2024Q4 2023
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$0.85$1.24+$0.39$3.19$564.77 million$587.86 million
2/22/2024Q4 2023
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$0.60-$1.26-$0.66-$1.26$131.14 million$132.51 million
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
N/AN/AN/AN/AN/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
0.94
3.45
2.18
ICU Medical, Inc. stock logo
ICUI
ICU Medical
0.74
2.53
1.06
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
7.13
7.10
6.95
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
84.78%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
96.10%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/A
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3.10%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
6.70%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.68%
Nevro Corp. stock logo
NVRO
Nevro
3.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3,94678.60 million76.17 millionOptionable
ICU Medical, Inc. stock logo
ICUI
ICU Medical
14,00024.37 million22.73 millionOptionable
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
2,00031.10 million30.89 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.51 millionOptionable

HAE, IART, NVRO, ICUI, and IRTC Headlines

SourceHeadline
Hold Rating on Nevro Corp Amidst Strong Q1 Performance and Conservative OutlookHold Rating on Nevro Corp Amidst Strong Q1 Performance and Conservative Outlook
markets.businessinsider.com - May 8 at 3:24 PM
Nevro Corp. (NYSE:NVRO) Q1 2024 Earnings Call TranscriptNevro Corp. (NYSE:NVRO) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 8 at 3:24 PM
Nevro (NYSE:NVRO) Price Target Lowered to $11.00 at Canaccord Genuity GroupNevro (NYSE:NVRO) Price Target Lowered to $11.00 at Canaccord Genuity Group
marketbeat.com - May 8 at 2:34 PM
Nevro (NYSE:NVRO) Issues Quarterly  Earnings ResultsNevro (NYSE:NVRO) Issues Quarterly Earnings Results
marketbeat.com - May 8 at 1:32 PM
Nevros (NVRO) Q1 Earnings and Sales Beat Estimates, Margins UpNevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up
zacks.com - May 8 at 1:16 PM
Nevro Corp (NVRO) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of Financial ...Nevro Corp (NVRO) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of Financial ...
finance.yahoo.com - May 8 at 5:23 AM
Nevro: Q1 Earnings SnapshotNevro: Q1 Earnings Snapshot
timesunion.com - May 7 at 7:22 PM
Nevro (NVRO) Reports Q1 Loss, Tops Revenue EstimatesNevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
zacks.com - May 7 at 6:31 PM
Nevro Reports First-Quarter 2024 Financial ResultsNevro Reports First-Quarter 2024 Financial Results
prnewswire.com - May 7 at 4:05 PM
Nevro earnings preview: what Wall Street is expectingNevro earnings preview: what Wall Street is expecting
markets.businessinsider.com - May 7 at 3:04 AM
Nevro Corp. (NYSE:NVRO) Receives Average Rating of "Hold" from AnalystsNevro Corp. (NYSE:NVRO) Receives Average Rating of "Hold" from Analysts
americanbankingnews.com - May 7 at 1:44 AM
Nevro (NVRO) Scheduled to Post Quarterly Earnings on TuesdayNevro (NVRO) Scheduled to Post Quarterly Earnings on Tuesday
americanbankingnews.com - May 5 at 3:34 AM
Nevro (NVRO) Scheduled to Post Earnings on TuesdayNevro (NVRO) Scheduled to Post Earnings on Tuesday
marketbeat.com - April 30 at 7:53 AM
Federated Hermes Inc. Has $9.28 Million Position in Nevro Corp. (NYSE:NVRO)Federated Hermes Inc. Has $9.28 Million Position in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 25 at 5:33 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Integra LifeSciences logo

Integra LifeSciences

NASDAQ:IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
ICU Medical logo

ICU Medical

NASDAQ:ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
iRhythm Technologies logo

iRhythm Technologies

NASDAQ:IRTC
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.